QSIHealthcare · Medical DevicesThe 3 Wall Street analysts covering Quantum-Si, Inc. hold a median 12-month price target of $1.9 — +30.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 31 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Quantum-Si, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (78): Sales and profits are climbing, and climbing faster than before.
Volatility (14): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on QSI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +30.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $4.00 |
| 5 Mar 2026 | Canaccord Genuity | Maintains | Hold | $1.50 → $1.00 |
| 5 Mar 2026 | Canaccord Genuity | Maintains | Hold | — |
| 22 Dec 2025 | Canaccord Genuity | Maintains | Hold | — |
| 27 Oct 2025 | Canaccord Genuity | Maintains | Hold | — |
| 9 Sept 2025 | Canaccord Genuity | Maintains | Hold | — |
| 19 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Feb 2025 | Alliance Global Partners | Initiates | Buy | — |
| 14 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Nov 2024 | Canaccord Genuity | Maintains | Hold | — |
| 13 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Dec 2023 | HC Wainwright & Co. | Initiates | Buy | — |
| 25 Sept 2023 | Canaccord Genuity | Downgrade | Hold | — |
| 20 Oct 2021 | Canaccord Genuity | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
QSI appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Quantum-Si, Inc. returned −28.1% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 3% of US stocks
Cheaper than 47% of US stocks
Cheaper than 77% of US stocks
Higher than 7% of US stocks
Higher than 62% of US stocks
Higher than 2% of US stocks
Higher than 95% of US stocks
Higher than 22% of US stocks
Higher than 16% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Quantum-Si, Inc. has a market value of $319.6M and an enterprise value of $274.6M.
Revenue in the twelve months to 30 June 2026: $1.6M. The latest quarter shrank 41.8% year on year.
Net income over the same four quarters: −$98.5M, a −6138.3% net margin.
Diluted earnings per share, trailing twelve months: $−0.46.
Free cash flow in the twelve months to 30 June 2026: −$93.7M.
Trailing P/E: −2.9×; forward P/E: −4.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Quantum-Si, Inc. employs 145 people — $11K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Quantum-Si, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Quantum-Si announced it will provide a business update and report its third-quarter 2026 financial results on November 5, 2026.
Why it matters — QSI watchers can note the date when the company plans to share its quarterly results and business update.
Quantum-Si said Nasdaq notified the company that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market under Listing Rule 5450(a)(1).
Why it matters — QSI watchers may note the company has regained compliance with a Nasdaq continued-listing requirement.
The article says Q4 has historically produced outsized S&P 500 returns, particularly after midterm election years, and outlines an “October breakout cycle” thesis. It highlights small-cap healthcare/biotech, technology, and consumer cyclical stocks as potential early breakout candidates.
Why it matters — The excerpt offers broad sector and market-seasonality context, but does not mention Quantum-Si, so it provides no company-specific information for QSI watchers.
The article discusses Neuralink’s brain-computer interface ambitions and notes that investors cannot buy Neuralink stock. Its headline points to two public stocks with a stake in the brain race, but the excerpt does not identify them.
Why it matters — A QSI watcher may note the broader public-market interest in brain-computer interface developments, though the excerpt provides no specific connection to Quantum-Si.
Quantum-Si Inc, along with Nektar Therapeutics and Pacific Biosciences, is drawing elevated options activity today as biotech stocks make volatile moves. Schaeffers Research identified these companies as targets of active put traders.
Why it matters — The report highlights notable options-market interest in QSI, which QSI watchers may view as an indicator of trader attention on the stock amid biotech sector volatility.
The 3 Wall Street analysts covering Quantum-Si, Inc. have a median 12-month price target of $1.9, with estimates ranging from $1 to $3.95. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Quantum-Si, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Quantum-Si, Inc. 43 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Quantum-Si, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (78 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +30.1% from the last close, and Ticker Nerd's factor model ranks Quantum-Si, Inc. 43 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Quantum-Si, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $3.95 over the next 12 months.
Quantum-Si, Inc. returned -28.1% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Quantum-Si Incorporated Class A Common Stock represents ownership in Quantum-Si Incorporated, a life sciences company focused on proteomics and single-molecule protein analysis. Quantum-Si develops benchtop instrumentation, consumables, and software designed to support next-generation protein sequencing and automated protein data interpretation.
The most recent item we track (GlobeNewsWire, 16 Oct 2026): "Quantum-Si to Provide a Business Update and Report Third Quarter 2026 Financial Results on November 5, 2026". Quantum-Si announced it will provide a business update and report its third-quarter 2026 financial results on November 5, 2026.
Quantum-Si Incorporated Class A Common Stock represents ownership in Quantum-Si Incorporated, a life sciences company focused on proteomics and single-molecule protein analysis. Quantum-Si develops benchtop instrumentation, consumables, and software designed to support next-generation protein sequencing and automated protein data interpretation. Its current product set includes the Platinum and Platinum Pro instruments, library preparation kits, sequencing kits, and analysis software used in protein identification, protein variant detection, biomarker research, antibody characterization, and post-translational modification analysis. The company serves research laboratories and scientific organizations that need tools for detailed protein-level investigation. Quantum-Si Incorporated Class A Common Stock reflects a market position tied to specialized biotechnology research tools and the broader demand for advanced protein analysis technologies in the life sciences sector.
CEO Mr. Jeffrey Alan Hawkins · 145 employees · United States · https://www.quantum-si.com
